{"country": "England & Wales", "charity_number": "1110009", "register_url": "https://register-of-charities.charitycommission.gov.uk/en/charity-search/?p_p_id=uk_gov_ccew_onereg_charitydetails_web_portlet_CharityDetailsPortlet&p_p_lifecycle=0&p_p_state=maximized&p_p_mode=view&_uk_gov_ccew_onereg_charitydetails_web_portlet_CharityDetailsPortlet_regId=1110009", "name": "THE UK STEM CELL FOUNDATION", "known_as": null, "other_names": [{"name": "PROPOSED NEW STEM CELL RESEARCH CHARITY", "name_type": "Previous name"}], "status": "Registered", "date_registered": "2005-06-14", "date_removed": null, "legal_form": "Charitable company", "area_of_benefit": "NATIONAL AND OVERSEAS", "address": "3rd floor 45 Albemarle Street, London", "postcode": "W1S 4JL", "phone": "02045724151", "email": "info@ukscf.org", "website": "www.ukscf.org", "lat": 51.50832, "lng": -0.141818, "activities": "The Key aim of the charity is to address the funding gap that hinders the translation of stem cell research into new treatments that have the potential for direct clinical benefit. The charity supports Universities, medical schools and hospitals in the United Kingdom for the benefit of the general public/mankind.", "purposes": null, "what_charity_does": null, "charitable_objects": "3.  THE CHARITABLE OBJECTS FOR WHICH THE COMPANY IS ESTABLISHED ARE THE PRESERVATION, PROMOTION AND ADVANCEMENT OF HUMAN HEALTH AND WELFARE AND THE ADVANCEMENT AND PROMOTION OF KNOWLEDGE AND EDUCATION FOR THE BENEFIT OF THE PUBLIC BY:  3.1   ENHANCING AND PROMOTING KNOWLEDGE OF AND ENGAGING IN, FUNDING AND SUPPORTING RESEARCH INTO THE MECHANISMS OF CELL DEGENERATION, REGENERATION AND MALFUNCTION AND THEIR LINKS TO DEGENERATIVE AND OTHER DISEASES, DISABILITIES, DISORDERS AND CONDITIONS IN RESPECT OF WHICH STEM CELL RELATED MEDICINES, TREATMENTS, CURES, DIAGNOSTICS, APPLICATIONS, THERAPIES, PRODUCTS OR TECHNOLOGIES MIGHT BE BENEFIT;  3.2   ENGAGING IN, FUNDING AND SUPPORTING RESEARCH INTO STEM CELL AND STEM CELL-BASED OR DERIVED METHODS AND TECHNOLOGIES, WITH A VIEW TO DISCOVERING, INVENTING, IMPROVING, DEVELOPING, PRODUCING AND APPLYING MEDICINE, TREATMENTS, CURES, DIAGNOSTICS, APPLICATIONS, THERAPIES, PRODUCTS AND TECHNOLOGIES AND OTHER MEDICINAL AGENTS, METHODS AND PROCESSES, INCLUDING THE TRANSLATION OF PURE RESEARCH INTO OUTPUTS TO A STANDARD SUSCEPTIBLE OF CLINICAL TRIALS WITH A VIEW TO ESTABLISHING THE EFFICACY AND SUPPORTING THE CLINICAL DEVELOPMENT OF MEDICINES, TREATMENTS, CURES, DIAGNOSTICS, APPLICATIONS, THERAPIES, PRODUCTS AND TECHNOLOGIES CAPABLE OF APPLICATION;  3.3  EDUCATING AND INFORMING THE PUBLIC IN RELATION TO STEM CELLS AND THE EFFICACY OF STEM CELL BASED OR DERIVED MEDICINES, TREATMENTS, CURES, DIAGNOSTICS, APPLICATIONS, THERAPIES, PRODUCTS AND TECHNOLOGIES AND OTHER MEDICINAL AGENTS, METHODS AND PROCESSES; AND  3.4  PROMOTING THE ETHICAL USE OF STEM CELLS WHETHER IN RESEARCH, DEVELOPMENT OR OTHERWISE AND THE ETHICAL USE AND PRODUCTION OF STEM CELLS AND STEM CELL BASED OR DERIVED MEDICINES, TREATMENTS, CURES, DIAGNOSTICS, APPLICATIONS, THERAPIES, PRODUCTS AND TECHNOLOGIES AND OTHER MEDICINAL AGENTS, METHODS AND PROCESSES AND THE APPROPRIATE REGULATION AND MANAGEMENT THEREOF AND EDUCATING AND INFORMING THE PUBLIC IN RELATION TO SUCH MATTERS.", "classifications": [{"type": "How", "code": 302, "description": "Makes Grants To Organisations"}, {"type": "How", "code": 307, "description": "Provides Advocacy/advice/information"}, {"type": "How", "code": 308, "description": "Sponsors Or Undertakes Research"}, {"type": "What", "code": 102, "description": "Education/training"}, {"type": "What", "code": 103, "description": "The Advancement Of Health Or Saving Of Lives"}, {"type": "Who", "code": 207, "description": "The General Public/mankind"}], "areas_of_operation": [{"area_type": "Region", "area_description": "Throughout England And Wales"}], "latest_income": 15282, "latest_expenditure": 178734, "fin_period_start": "2024-01-01", "fin_period_end": "2024-12-31", "financial_years": [{"start": "2024-01-01", "end": "2024-12-31", "income": 15282, "expenditure": 178734, "assets": null, "funds": null, "num_employees": null, "accounts_url": null}, {"start": "2023-01-01", "end": "2023-12-31", "income": 122402, "expenditure": 380269, "assets": null, "funds": null, "num_employees": null, "accounts_url": null}, {"start": "2022-01-01", "end": "2022-12-31", "income": 28368, "expenditure": 320722, "assets": null, "funds": null, "num_employees": null, "accounts_url": null}, {"start": "2021-01-01", "end": "2021-12-31", "income": 52775, "expenditure": 317667, "assets": null, "funds": null, "num_employees": null, "accounts_url": null}, {"start": "2020-01-01", "end": "2020-12-31", "income": 285248, "expenditure": 344151, "assets": null, "funds": null, "num_employees": null, "accounts_url": null}], "documents": [], "trustees": [{"name": "Caroline Chang", "chair": true, "appointment": "2025-01-02"}, {"name": "JAMES TAYLOR", "chair": false, "appointment": "2012-10-08"}, {"name": "Trevor Michael Phillips", "chair": false, "appointment": "2025-01-02"}]}